| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. | Clin Cancer Res | 2011 | 1.19 |
| 2 | Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. | Eur J Cancer | 2013 | 1.17 |
| 3 | High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. | Gynecol Oncol | 2012 | 1.06 |
| 4 | Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. | PLoS One | 2012 | 0.87 |
| 5 | Synchronous ovarian and endometrial cancer--an international multicenter case-control study. | Int J Gynecol Cancer | 2014 | 0.81 |
| 6 | Aromatase inhibitors in premenopausal women: the need for proper contraceptive counseling. | Breast J | 2006 | 0.76 |
| 7 | Residual tumor after neoadjuvant chemotherapy and interval debulking surgery for advanced endometrial cancer. | Gynecol Oncol | 2009 | 0.75 |